Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 21 Jun 2021
Factors associated with generic drug uptake in the United States, 2012 to 2017
19 June 2021 - In the United States, brand-name prescription drugs remain expensive until market exclusivity ends and lower cost generics ...
Posted by Michael Wonder on 21 Jun 2021
Are drugs priced in accordance with value? A comparison of value based and net prices using Institute for Clinical and Economic Review reports
19 June 2021 - The Institute for Clinical and Economic Review is an independent organisation that reviews drugs and devices with ...
Posted by Michael Wonder on 21 Jun 2021
BeiGene announces China NMPA approval of Brukinsa (zanubrutinib) for the treatment of patients with relapsed or refractory Waldenström’s macroglobulinaemia
18 June 2021 - Third approval for Brukinsa in China and second approval in Waldenström’s macroglobulinaemia worldwide. ...
Posted by Michael Wonder on 21 Jun 2021
TGA not expecting Novavax quality data until September
20 June 2021 - Australian’s medicines regulator says it does not expect key data from the country’s third major COVID-19 ...
Posted by Michael Wonder on 21 Jun 2021
Cystic fibrosis life-altering drug nearing patient access across the country: Health Canada
20 June 2021 - For the cystic fibrosis community, persistence and constant belief are paying off. ...
Posted by Michael Wonder on 21 Jun 2021
Health equity and Medicaid transformation — operationalising President Biden’s agenda
19 June 2021 - President Biden has made reforms intended to “protect and strengthen Medicaid” a centrepiece of his health policy ...
Posted by Michael Wonder on 20 Jun 2021
AstraZeneca welcomes court ruling on supply of its COVID-19 vaccine to Europe
18 June 2021 - AstraZeneca today welcomed the ruling by the Court of First Instance in Brussels. The European Commission had ...
Posted by Michael Wonder on 20 Jun 2021
US plays catch-up with Europe over biosimilar patents
17 June 2021 - Moves to ease market access for generic drug makers are gaining momentum. ...
Posted by Michael Wonder on 20 Jun 2021
Greg Hunt says no to health insurers creep into US style managed care
19 June 2021 - Federal Health Minister Greg Hunt has put Australian health funds on notice that the government does ...
Posted by Michael Wonder on 20 Jun 2021
Expensive brain cancer drug no longer an option under Medicare
19 June 2021 - Brain tumour experts and patient advocates are among those decrying a decision by the seller of ...
Posted by Michael Wonder on 20 Jun 2021
United States to spend $4.2 billion on anti-viral pills and other treatments for COVID-19
18 June 2021 - The United States is devoting $US3.2 billion ($4.2 billion) to speed development of antiviral pills to treat ...
Posted by Michael Wonder on 19 Jun 2021
European regulator EMA says it won't set 50% efficacy threshold for COVID shots
18 June 2021 - The EMA said on Thursday it would not impose a 50% efficacy threshold for COVID-19 vaccines, ...
Posted by Michael Wonder on 19 Jun 2021
HutchMed announces NMPA approval of surufatinib (Sulanda in China) for advanced pancreatic neuroendocrine tumours
18 June 2021 - Second new drug application approved for Sulanda in China. ...
Posted by Michael Wonder on 18 Jun 2021
The FDA grants a breakthrough device designation to the MIScoli, an innovative vertebral body tethering device to treat idiopathic scoliosis
18 June 2021 - Spinologics announced today that the U.S. FDA has granted the company a breakthrough device designation for its ...
Posted by Michael Wonder on 18 Jun 2021
3D bioprinting can help end organ transplant waitlists — if the FDA stops delaying
18 June 2021 - Right now, more than 100,000 Americans are waiting for organ transplants. Due to a lack of ...